全球乌司他丁市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

乌司他单抗市场分析

乌司他单抗市场正在经历强劲增长，这得益于其在治疗牛皮癣、克罗恩病和溃疡性结肠炎等自身免疫性疾病方面的有效性。这种以 Stelara 品牌销售的单克隆抗体靶向白细胞介素 12 和白细胞介素 23 通路，为患有慢性炎症的患者提供显著的治疗益处。最近的发展包括扩大适应症和正在进行的临床试验，以探索其对其他疾病（如强直性脊柱炎）的疗效。该市场的特点是人们对自身免疫性疾病的认识和诊断率不断提高，这促使对创新疗法的需求增加。此外，配方和给药方法的进步正在提高患者的依从性和治疗效果。竞争策略，包括制药公司之间的伙伴关系和合作，也促进了市场动态。总体而言，随着医疗保健提供者越来越认识到乌司他单抗改善复杂自身免疫性疾病患者生活质量的潜力，乌司他单抗市场有望继续扩张。

乌司他单抗市场规模

2023 年全球乌司他单抗市场规模价值 114 亿美元，预计到 2031 年将达到 180.3 亿美元，2024 年至 2031 年预测期内的复合年增长率为 5.90%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

乌司他单抗市场趋势

“自身免疫性疾病患病率不断上升”

The ustekinumab market is evolving rapidly, fueled by increasing prevalence rates of autoimmune diseases such as psoriasis, Crohn’s disease, and ulcerative colitis. This monoclonal antibody, effective in targeting interleukin-12 and interleukin-23, is gaining popularity for its significant therapeutic benefits and favorable safety profile. Recent innovations include the development of biosimilars, providing cost-effective alternatives and increasing accessibility for patients. Another notable trend is the growing interest in combination therapies that enhance the efficacy of Ustekinumab by integrating it with other treatment modalities. In addition, advancements in patient monitoring and personalized medicine are driving tailored treatment approaches, improving patient outcomes. As healthcare providers and patients increasingly recognize the importance of managing chronic inflammatory conditions effectively, the ustekinumab market is expected to see substantial growth, positioning it as a cornerstone in the treatment of autoimmune diseases. Overall, the market is on a positive trajectory, driven by innovation and heightened awareness.

Report Scope and Ustekinumab Market Segmentation         

Ustekinumab Market Definition

Ustekinumab is a monoclonal antibody that selectively targets interleukin-12 (IL-12) and interleukin-23 (IL-23), two key cytokines involved in the inflammatory processes of autoimmune diseases. Approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis, Crohn's disease, and ulcerative colitis, Ustekinumab works by inhibiting these cytokines, thereby reducing inflammation and the immune response associated with these conditions. Administered via subcutaneous injection, it has shown significant efficacy in improving symptoms and the quality of life for patients suffering from chronic inflammatory disorders. s

Ustekinumab Market Dynamics

Drivers

• Expanded Therapeutic Indications

The increasing availability of advanced diagnostic technologies has significantly improved the detection and diagnosis of autoimmune disorders, such as Crohn's disease, psoriasis, and ulcerative colitis. Tools like advanced imaging, biomarker testing, and genetic profiling enable earlier and more accurate identification of these conditions. Simultaneously, growing awareness campaigns, both from healthcare providers and patient advocacy groups, have educated the public on the symptoms and risks of autoimmune diseases. This heightened awareness leads to earlier medical consultations and diagnoses, enabling timely treatment interventions. As a result, the demand for biologic therapies like Ustekinumab has risen, as patients are identified and treated earlier in the disease progression. This trend serves as a key market driver, fostering growth in the Ustekinumab market as more patients seek effective treatments.

•  Development of Biosimilars

The introduction of ustekinumab biosimilar is set to significantly enhance accessibility and affordability for patients suffering from autoimmune diseases. As healthcare costs continue to rise, biosimilars provide a cost-effective alternative to the original ustekinumab therapy, making it more accessible to a broader patient population. This increased affordability can lead to higher treatment adherence and improved patient outcomes, particularly in underserved communities where financial constraints often limit access to advanced therapies. Furthermore, the availability of biosimilars is likely to foster healthy competition in the market, driving prices down and encouraging further innovation among pharmaceutical companies. As healthcare systems recognize the benefits of biosimilars, the overall demand for ustekinumab and its biosimilars will likely increase, further propelling market growth and ensuring that more patients receive effective treatment for chronic inflammatory conditions.

Opportunities

• Development of Combination Therapies

Investigating ustekinumab's efficacy in combination with other therapies presents a promising market opportunity for enhancing treatment outcomes in patients with complex autoimmune conditions. Research indicates that using ustekinumab alongside conventional therapies or other biologics may lead to improved efficacy and reduced disease activity. This synergistic approach can address the multifaceted nature of autoimmune diseases, which often require a combination of therapeutic strategies for optimal management. By exploring various combination therapies, healthcare providers can offer more personalized treatment plans that cater to individual patient needs, ultimately improving quality of life. Furthermore, the potential success of these combinations may attract additional clinical interest and investment, driving innovation in the ustekinumab market and expanding its application across various therapeutic areas.

• Telemedicine Integration

The rise of telemedicine presents significant opportunities for improved patient management and monitoring in the ustekinumab market. With the increasing adoption of telehealth services, healthcare providers can offer real-time consultations, follow-ups, and support, making it easier for patients to engage with their treatment plans. This enhanced accessibility can lead to more consistent use of ustekinumab, as patients can communicate with their healthcare teams without the barriers of travel or time constraints. Furthermore, telemedicine enables healthcare providers to monitor patient progress closely, allowing for timely adjustments to treatment protocols when necessary. Improved communication and support can also boost patient adherence to prescribed therapies, ultimately leading to better health outcomes and reinforcing the role of ustekinumab as a critical component in managing autoimmune diseases.

Restraints/Challenges

• High Costs of Treatments

The high expense associated with ustekinumab therapy poses a significant challenge for many patients, particularly in regions with limited insurance coverage or high out-of-pocket costs. For individuals diagnosed with chronic autoimmune conditions such as psoriasis, Crohn's disease, or ulcerative colitis, the financial burden of Ustekinumab can be overwhelming, leading to treatment delays or discontinuation. This economic barrier affects access to the medication and  diminishes patient adherence to prescribed treatment protocols. Patients who struggle to afford their medications may be more likely to miss doses or abandon treatment altogether, which can result in a deterioration of their condition. Consequently, the high costs associated with ustekinumab therapy present a substantial challenge in ensuring equitable access and optimal treatment outcomes for patients in need.

• Underdeveloped Healthcare Infrastructures

In regions with underdeveloped healthcare infrastructures, the effective deployment of ustekinumab is often hindered by several significant challenges. Inadequate healthcare access means that patients may struggle to receive timely diagnoses and appropriate treatments, limiting their opportunities to benefit from Ustekinumab therapy. Furthermore, limited treatment options in these areas can exacerbate the problem, as patients may not have access to specialists familiar with biologics or advanced therapies. This lack of access can result in delayed treatment initiation or a complete lack of treatment for those in need. In addition, inadequate infrastructure can impact the supply chain, making it difficult for healthcare providers to obtain ustekinumab consistently. Consequently, these barriers restrict patient access to this crucial medication and  impede overall market growth in these regions.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Ustekinumab Market Scope

The market is segmented on the basis of drug class, demographic, application, dosage form, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Interleukin Inhibitors
• Others

人口统计

• 成人
• 儿科

  应用

• 关节炎
• 结肠炎
• 红斑狼疮
• 多发性肌炎伴有掌跖脓疱病
• 肝硬化
• 结节病
• 糖尿病
• 其他的

剂型

• 静脉注射液
• 皮下注射液

最终用户

• 诊所
• 医院
• 其他的

分销渠道

• 医院药房
• 零售药店
• 网上药店

乌司他丁市场区域分析

对市场进行分析，并按上述国家、药品类别、人口统计、应用、剂型、最终用户和分销渠道提供市场规模洞察和趋势。

市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

北美在 Ustekinumab 市场处于领先地位，这主要归功于大型制药公司的集中以及行业内主要参与者的强大影响力。该地区的可支配收入较高，这使得患者能够获得先进的治疗选择。此外，完善的医疗基础设施支持 Ustekinumab 的有效分销和管理，进一步巩固了其在该市场的主导地位。

预计亚太地区将在 2024 年至 2031 年期间经历显著增长，这得益于旨在增强治疗方案的研发活动的激增。政府对医疗保健计划和该领域创新的支持增加预计将进一步提振市场。此外，该地区庞大人口对先进疗法的需求不断增长，将有助于亚太地区 Ustekinumab 市场的积极前景。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。  

乌司他单抗市场份额

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

在市场上运营的 Ustekinumab 市场领导者是：

• 富士制药株式会社（日本）
• 明治控股株式会社（日本）
• 田边三菱制药株式会社（日本）
• STADA Arzneimittel AG（德国）
• Formycon AG（德国）
• NeuClone（澳大利亚）
• Outlook Therapeutics, Inc.（美国）
• BioXpress Therapeutics SA（瑞士）
• 强生私人有限公司（美国）
• 杨森制药公司（美国）
• Apino Pharma 株式会社 (日本)
• Synergia Life Sciences Pvt. Ltd.（印度）

乌司他单抗市场最新动态

• 2024 年 7 月，Celltrion 宣布加拿大卫生部批准了 Steqeyma（开发名称 CT-P43）的新药申请 (NDS)，这是一种用于治疗自身免疫性疾病的生物仿制药。该生物仿制药以 Stelara 为蓝本，扩大了牛皮癣和克罗恩病等疾病患者的治疗选择。该批准对 Celltrion 来说是一个重要的里程碑，增强了加拿大获得治疗自身免疫性疾病的有效疗法的机会
• 2020 年 7 月，富士胶片协和麒麟生物制剂公司在日本获得了该国首个阿达木单抗生物仿制药的批准，涵盖牛皮癣、强直性脊柱炎和克罗恩病等疾病。该批准提高了慢性炎症疾病生物疗法的可及性。生物仿制药的推出促进了竞争和可负担性，间接刺激了对乌司他单抗等生物制剂的需求
• 2020 年 8 月，Lupin Limited 和 Mylan 在 2020 年 5 月获得欧盟委员会的上市许可后，推出了其生物仿制药依那西普 Nepexto。Nepexto 获批用于治疗银屑病关节炎和斑块状银屑病等疾病，可提供更方便、更实惠的治疗选择。此次上市增强了欧洲生物制剂市场的竞争，进一步推动了对 Ustekinumab 等替代品的需求

SKU-67573